Company Overview of MPM Capital
MPM Capital is a private equity and venture capital firm specializing in seed, startup, early ventures, emerging growth, middle market, mature, mid venture, late venture, buyout, recapitalization, PIPES, and growth equity investments. The firm makes its venture investments through its MPM BioVentures fund and invests in the public markets through MPM BioEquities hedge fund. It invests in growth stage in in the biotechnology, healthcare, and life sciences sector. It invests in the seed stage through early clinical development stage of a company and invests in late stage in biopharmaceutical and diagnostics companies with clinical proof-of-concept data. It prefers to invest in medical technolo...
450 Kendall Street
Cambridge, MA 02142
Founded in 1996
Key Executives for MPM Capital
Managing Director and Managing Partner
Chief Operating Officer and General Counsel
Compensation as of Fiscal Year 2014.
MPM Capital Key Developments
MPM Capital Appoints Gregory Sieczkiewicz as Managing Director and Chief Counsel of Intellectual Property
Apr 13 15
MPM Capital announced the appointment of Gregory Sieczkiewicz as Managing Director and Chief Counsel, Intellectual Property, effective immediately. Greg will also provide IP counsel to MPM and serve as start-up IP counsel to MPM portfolio companies. In his most recent role, Greg served as Vice President, Intellectual Property, Flagship Ventures where, among other accomplishments, Greg drove the issuance of first-in-field US patents for oral biologics and served as the IP architect and co-inventor of nucleic acid therapeutics patent estate.
MPM Capital Appoints Anthony (Tony) Rosenberg as Managing Director, Effective Immediately
Apr 2 15
MPM Capital announced the appointment of long-time Novartis M&A and Licensing executive Anthony (Tony) Rosenberg as Managing Director, effective immediately. Tony will serve as a strategic advisor and board member to MPM portfolio companies, advancing MPM's proven strategy of identifying promising assets and assembling teams to build commercially successful companies.
MPM Capital Appoints Patrick A. Baeuerle as Managing Director, Effective April 1
Mar 21 15
MPM Capital has appointed Dr. Patrick A. Baeuerle as Managing Director, effective April 1. Dr. Baeuerle is responsible for the development of BiTE antibody BLYNCYTO (blinatumomab; AMG 103) which was approved in under three months by the US FDA for therapy of relapsed/refractory ALL (following breakthrough therapy designation and priority review). Most recently, he served as Vice President, Research, and General Manager, Amgen Research (Munich) GmbH, where he oversaw translational science as well as BiTE development, and served as site head.
Similar Private Companies By Industry
Recent Private Companies Transactions